Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868668 | 0.83 | LMNA (0.32) | LMNANAMPT | |
| SCHEMBL24433786 | 0.80 | SCN5A (0.32) | SCN5ASCN2A | |
| SCHEMBL14868695 | 0.77 | TAAR1 (0.39) | SCN5ASCN2A | |
| SCHEMBL24433679 | 0.76 | SCN5A (0.32) | SCN5ASCN2A | |
| SCHEMBL14868318 | 0.76 | SCN5A (0.48) | SCN5ASCN2ALMNA | |
| SCHEMBL28128797 | 0.76 | SCN5A (0.48) | SCN5ASCN2ALMNA | |
| SCHEMBL14868754 | 0.75 | METAP2 (0.35) | SCN5ASCN2ALMNANAMPT | |
| SCHEMBL14868444 | 0.75 | MAPT (0.51) | LMNA | |
| SCHEMBL14868731 | 0.72 | HRH4 (0.33) | SCN5ASCN2A | |
| SCHEMBL14868693 | 0.72 | CNR2 (0.39) | SCN5ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | SCN5A 1195/4885SCN2A 2250/4885LMNA 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.